Drug Type Bispecific antibody |
Synonyms RR 1752, RR1752 |
Target |
Mechanism ROCK1 inhibitors(Rho-associated protein kinase 1 inhibitors), Serine/threonine-protein kinase Aurora inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Myelofibrosis | Preclinical | US | 11 Dec 2023 |